ERBB2 and cancer: As a result, radiolabelling HER2 aptamers with actinium-225 to produce [225Ac]Ac-aptamers could provide highly targeted and efficacious cancer treatments and improve patient prognosis in not only people suffering from primary and metastatic cancers, but also chemotherapeutic and conventional radiotherapy-resistant patients.